What to Do and Not Do as Regulatory Enforcement Increases for Life Sciences Communications hosted by BIO

  • Share:
Name: What to Do and Not Do as Regulatory Enforcement Increases for Life Sciences Communications hosted by BIO
Date: April 13, 2023
Time: 2:00 PM - 3:00 PM EDT
Website: Register Now!
Event Description:
U.S. Department of Justice (DOJ) statistics suggest that enforcement will be a top government priority in 2023, including for pharma/life sciences. Warning or untitled letters from the U.S. Food and Drug Administration (FDA) will serve as ammunition for DOJ cases. Statements about product safety will be heavily scrutinized. Do you know what to watch out for? Has your company trained its employees and marketing agencies on how to appropriately implement the requirements for promotion? What activities require extra vigilance? The prior downturn in enforcement can be linked to the development of a response to COVID-19, which diverted government resources across the board. Now trends suggest the FDA, DOJ, and Office of Inspector General (OIG) will return to active healthcare enforcement in 2023 for violations of the Food Drug and Cosmetic Act (FDCA), False Claims Act and the Anti-Kickback Statute in part attributable to the goal of obtaining additional financial recoveries.

Webinar's learning objectives:
  • Understand the current trends for government enforcement
  • Dissect the implications of increased enforcement on the industry
  • Identify specific cases that are clear examples for company concern
  • Isolate the key principles for avoiding violations
Location:
Webinar
Set a Reminder:
Enter your email address below to receive a reminder message.